{"id":5517,"date":"2016-02-04T22:57:00","date_gmt":"2016-02-04T22:57:00","guid":{"rendered":"http:\/\/associatednews.us\/content\/2016\/02\/04\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays\/"},"modified":"2016-02-04T22:57:00","modified_gmt":"2016-02-04T22:57:00","slug":"house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays","status":"publish","type":"post","link":"https:\/\/associatednews.us\/content\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays\/","title":{"rendered":"House Hearing Probes The Mystery Of High Drug Prices That &#039;Nobody Pays&#039;"},"content":{"rendered":"<p><span style=\"font-style:italic;font-size:16px\">By  <a class=\"colorbox\" href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare\">Alison Kodjak<\/a><\/span>  <\/p>\n<div class=\"ftpimagefix\" style=\"float:left\"><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare\"><img decoding=\"async\" width=\"150\" src=\"http:\/\/media.npr.org\/assets\/img\/2016\/02\/04\/nancy-retzlaff_custom-2daa4684fd54c6c4f7aaf0a3e40e515f223b77bf-s1100-c15.jpg\" title=\"Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, was asked how much the drug Daraprim costs at the House Oversight and Government Reform Committee on Capitol Hill on Thursday.\" alt=\"Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, was asked how much the drug Daraprim costs at the House Oversight and Government Reform Committee on Capitol Hill on Thursday.\"><\/a><\/div>\n<div><strong><\/strong> <strong>3:39<\/strong><\/div>\n<p><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/pd.npr.org\/anon.npr-mp3\/npr\/atc\/2016\/02\/20160204_atc_former_drug_ceo_martin_shkreli_pleads_the_fifth_before_house_panel.mp3?dl=1\"><span>Download<\/span><\/a><\/p>\n<div>\n<div>\n<div><\/div>\n<div>\n<div>\n<p>Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, was asked how much the drug Daraprim costs at the House Oversight and Government Reform Committee on Capitol Hill on Thursday. <strong>Brendan Smialowski\/AFP\/Getty Images<\/strong> <strong>hide caption<\/strong><\/p>\n<\/div>\n<p><strong>toggle caption<\/strong> <span>Brendan Smialowski\/AFP\/Getty Images<\/span><\/div>\n<\/div>\n<p>Members of Congress at a Thursday hearing wrestled with questions about why the prices of some old drugs are rising so fast.<\/p>\n<p>Much of the <a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/thetwo-way\/2016\/02\/04\/465548279\/no-comment-from-grinning-martin-shkreli-at-house-hearing-on-drug-prices\">session<\/a> held by the House Oversight and Government Reform Committee was dominated by Martin Shkreli, the bad-boy former CEO of Turing Pharmaceuticals who earned notoriety by raising the price 5,000 percent for the drug Daraprim, a treatment for toxoplasmosis.<\/p>\n<p>Shkreli \u2014 who has been indicted on unrelated securities charges and pleaded not guilty \u2014 invoked his Fifth Amendment right against self-incrimination and refused to answer questions. As the hearing went on, he smirked, rolled his eyes and chuckled. Afterward, he insulted the committee members on Twitter.<\/p>\n<div>\n<blockquote>\n<p lang=\"en\" dir=\"ltr\">Hard to accept that these imbeciles represent the people in our government.<\/p>\n<p>\u2014 Martin Shkreli (@MartinShkreli) <a class=\"colorbox\" rel=\"nofollow\" href=\"https:\/\/twitter.com\/MartinShkreli\/status\/695264859907317761\">February 4, 2016<\/a><\/p><\/blockquote>\n<\/div>\n<p>Committee member Rep. Ted Lieu, D-Calif., tweeted back.<\/p>\n<div>\n<blockquote>\n<p lang=\"en\" dir=\"ltr\">You know what&#8217;s sort of cool <a class=\"colorbox\" rel=\"nofollow\" href=\"https:\/\/twitter.com\/MartinShkreli\">@MartinShkreli<\/a>? That I represent the people and you are under federal indictment. <a class=\"colorbox\" rel=\"nofollow\" href=\"https:\/\/t.co\/acQvPEuPrT\">https:\/\/t.co\/acQvPEuPrT<\/a><\/p>\n<p>\u2014 Ted Lieu (@tedlieu) <a class=\"colorbox\" rel=\"nofollow\" href=\"https:\/\/twitter.com\/tedlieu\/status\/695273475229949952\">February 4, 2016<\/a><\/p><\/blockquote>\n<\/div>\n<p>Once Shkreli left Thursday&#8217;s hearing, lawmakers grilled other witnesses about rising drug prices.<\/p>\n<p>The seemingly simple question about how much Daraprim costs in the real world proved pretty tricky to pin down.<\/p>\n<p>Listen for yourself as Rep. Peter Welch, D-Vt., asked Turing&#8217;s Chief Commercial Officer Nancy Retzlaff how much Daraprim costs. The response is enough to make us feel like imbeciles.<\/p>\n<div>\n<div>\n<div><\/div>\n<div>\n<div>\n<div><\/div>\n<div>\n<h3><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare#\">Rep. Welch ask Turing&#8217;s Nancy Retzlaff about Daraprim pricing<\/a><\/h3>\n<h3>Loading\u2026<\/h3>\n<p><strong> 2:55 <\/strong><\/div>\n<\/div>\n<ul>\n<li><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare#\" title=\"Playlist\">Playlist<\/a><\/li>\n<li><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare#\" title=\"Embed\">Embed<\/a>\n<div><label>Embed<\/label> <button>Close embed overlay<\/button> <strong><code><strong>&lt;<\/b>iframe src=\"http:\/\/www.npr.org\/player\/embed\/465604320\/465617672\" width=\"100%\" height=\"290\" frameborder=\"0\" scrolling=\"no\" title=\"NPR embedded audio player\"&gt;<\/strong><\/code><\/strong><\/div>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p>Rep. Welch ask Turing&#8217;s Nancy Retzlaff about Daraprim pricing<\/p>\n<\/div>\n<\/div>\n<p><em>This entry passed through the Full-Text RSS service &#8211; if this is your content and you&#8217;re reading it on someone else&#8217;s site, please read the FAQ at fivefilters.org\/content-only\/faq.php#publishers.<\/em><\/p>\n<p>Source:: <a href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare\" class=\"colorbox\" title=\"House Hearing Probes The Mystery Of High Drug Prices That &#039;Nobody Pays&#039;\" rel=\"nofollow\">http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<div class=\"ftpimagefix\" style=\"float:left\"><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare\"><img decoding=\"async\" width=\"150\" src=\"http:\/\/media.npr.org\/assets\/img\/2016\/02\/04\/nancy-retzlaff_custom-2daa4684fd54c6c4f7aaf0a3e40e515f223b77bf-s1100-c15.jpg\" title=\"Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, was asked how much the drug Daraprim costs at the House Oversight and Government Reform Committee on Capitol Hill on Thursday.\" alt=\"Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, was asked how much the drug Daraprim costs at the House Oversight and Government Reform Committee on Capitol Hill on Thursday.\"><\/a><\/div>\n<div><strong><\/strong> <strong>3:39<\/strong><\/div>\n<p><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/pd.npr.org\/anon.npr-mp3\/npr\/atc\/2016\/02\/20160204_atc_former_drug_ceo_martin_shkreli_pleads_the_fifth_before_house_panel.mp3?dl=1\"><span>Download<\/span><\/a><\/p>\n<div>\n<div>\n<div><\/div>\n<div>\n<div>\n<p>Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, was asked how much the drug Daraprim costs at the House Oversight and Government Reform Committee on Capitol Hill on Thursday. <strong>Brendan Smialowski\/AFP\/Getty Images<\/strong> <strong>hide caption<\/strong><\/p>\n<\/div>\n<p><strong>toggle caption<\/strong> <span>Brendan Smialowski\/AFP\/Getty Images<\/span><\/div>\n<\/div>\n<p>Members of Congress at a Thursday hearing wrestled with questions about why the prices of some old drugs are rising so fast.<\/p>\n<p>Much of the <a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/thetwo-way\/2016\/02\/04\/465548279\/no-comment-from-grinning-martin-shkreli-at-house-hearing-on-drug-prices\">session<\/a> held by the House Oversight and Government Reform Committee was dominated by Martin Shkreli, the bad-boy former CEO of Turing Pharmaceuticals who earned notoriety by raising the price 5,000 percent for the drug Daraprim, a treatment for toxoplasmosis.<\/p>\n<p>Shkreli \u2014 who has been indicted on unrelated securities charges and pleaded not guilty \u2014 invoked his Fifth Amendment right against self-incrimination and refused to answer questions. As the hearing went on, he smirked, rolled his eyes and chuckled. Afterward, he insulted the committee members on Twitter.<\/p>\n<div>\n<blockquote>\n<p lang=\"en\" dir=\"ltr\">Hard to accept that these imbeciles represent the people in our government.<\/p>\n<p>\u2014 Martin Shkreli (@MartinShkreli) <a class=\"colorbox\" rel=\"nofollow\" href=\"https:\/\/twitter.com\/MartinShkreli\/status\/695264859907317761\">February 4, 2016<\/a><\/p><\/blockquote>\n<\/div>\n<p>Committee member Rep. Ted Lieu, D-Calif., tweeted back.<\/p>\n<div>\n<blockquote>\n<p lang=\"en\" dir=\"ltr\">You know what&#8217;s sort of cool <a class=\"colorbox\" rel=\"nofollow\" href=\"https:\/\/twitter.com\/MartinShkreli\">@MartinShkreli<\/a>? That I represent the people and you are under federal indictment. <a class=\"colorbox\" rel=\"nofollow\" href=\"https:\/\/t.co\/acQvPEuPrT\">https:\/\/t.co\/acQvPEuPrT<\/a><\/p>\n<p>\u2014 Ted Lieu (@tedlieu) <a class=\"colorbox\" rel=\"nofollow\" href=\"https:\/\/twitter.com\/tedlieu\/status\/695273475229949952\">February 4, 2016<\/a><\/p><\/blockquote>\n<\/div>\n<p>Once Shkreli left Thursday&#8217;s hearing, lawmakers grilled other witnesses about rising drug prices.<\/p>\n<p>The seemingly simple question about how much Daraprim costs in the real world proved pretty tricky to pin down.<\/p>\n<p>Listen for yourself as Rep. Peter Welch, D-Vt., asked Turing&#8217;s Chief Commercial Officer Nancy Retzlaff how much Daraprim costs. The response is enough to make us feel like imbeciles.<\/p>\n<div>\n<div>\n<div><\/div>\n<div>\n<div>\n<div><\/div>\n<div>\n<h3><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare#\">Rep. Welch ask Turing&#8217;s Nancy Retzlaff about Daraprim pricing<\/a><\/h3>\n<h3>Loading\u2026<\/h3>\n<p><strong> 2:55 <\/strong><\/div>\n<\/div>\n<ul>\n<li><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare#\" title=\"Playlist\">Playlist<\/a><\/li>\n<li><a class=\"colorbox\" rel=\"nofollow\" href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/02\/04\/465604320\/house-hearing-probes-the-mystery-of-high-drug-prices-that-nobody-pays?utm_medium=RSS&amp;utm_campaign=healthcare#\" title=\"Embed\">Embed<\/a>\n<div><label>Embed<\/label> <button>Close embed overlay<\/button> <strong><code><strong>&lt;<\/b>iframe src=\"http:\/\/www.npr.org\/player\/embed\/465604320\/465617672\" width=\"100%\" height=\"290\" frameborder=\"0\" scrolling=\"no\" title=\"NPR embedded audio player\"&gt;<\/strong><\/code><\/strong><\/div>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p>Rep. Welch ask Turing&#8217;s Nancy Retzlaff about Daraprim pricing<\/p>\n<\/div>\n<\/div>\n<p><em>This entry passed through the Full-Text RSS service &#8211; if this is your content and you&#8217;re reading it on someone else&#8217;s site, please read the FAQ at fivefilters.org\/content-only\/faq.php#publishers.<\/em><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[47],"tags":[],"class_list":["post-5517","post","type-post","status-publish","format-standard","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/associatednews.us\/content\/wp-json\/wp\/v2\/posts\/5517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/associatednews.us\/content\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/associatednews.us\/content\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/associatednews.us\/content\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/associatednews.us\/content\/wp-json\/wp\/v2\/comments?post=5517"}],"version-history":[{"count":0,"href":"https:\/\/associatednews.us\/content\/wp-json\/wp\/v2\/posts\/5517\/revisions"}],"wp:attachment":[{"href":"https:\/\/associatednews.us\/content\/wp-json\/wp\/v2\/media?parent=5517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/associatednews.us\/content\/wp-json\/wp\/v2\/categories?post=5517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/associatednews.us\/content\/wp-json\/wp\/v2\/tags?post=5517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}